Randomised Trial of Mycophenolate Mofetil Versus Azathioprine for Treatment of Chronic Active Crohn's Disease

Overview

Journal Gut

Specialty Gastroenterology

Date 1999 Apr 16

PMID 10205197

Citations 29

Authors

M F Neurath

R Wanitschke

M Peters

F Krummenauer

K H Meyer zum Buschenfelde

J F Schlaak

Affiliations

Soon will be listed here.

Abstract

Background: Crohn's disease is a chronic inflammatory disease of the alimentary tract. Azathioprine is an effective agent in the management of chronic active Crohn's disease leading to long term remission of disease activity. Such treatment leads to limited efficacy or side effects in a small subset of patients.

Aims: To compare efficacy and side effects of treatment with azathioprine plus corticosteroids versus mycophenolate mofetil (MMF) plus corticosteroids in patients with chronic active Crohn's disease.

Methods: Seventy patients with chronic active Crohn's disease (Crohn's disease activity index (CDAI) greater than 150) were randomised for treatment with azathioprine/cortisone or MMF/cortisone. Corticosteroid dosage was tapered according to a standard protocol. Disease activity was monitored by clinical scores after one, two, three, and six months.

Results: Treatment of patients with moderately active (CDAI 150-300) Crohn's disease with MMF/cortisone led to a significant reduction in clinical activity scores comparable to treatment with azathioprine/cortisone. Treatment of patients with highly active Crohn's disease (CDAI greater than 300) with MMF/cortisone caused significant suppression of clinical activity earlier than azathioprine/cortisone treatment. Treatment with MMF/cortisone was associated with few adverse effects.

Conclusion: Treatment of chronic active Crohn's disease with MMF plus cortisone appears to be effective and well tolerated and should be considered in patients allergic to azathioprine or in whom azathioprine has failed.

Citing Articles

Mycophenolate Mofetil Appears Effective for the Treatment of Patients With Refractory Crohn's Disease.

Rosenfeld S, Clark-Snustad K, Kamp K, Jacobs J, Barahimi M, Harper J Crohns Colitis 360. 2024; 6(4):otae067.

PMID: 39703698 PMC: 11655623. DOI: 10.1093/crocol/otae067.

Fungal Microbiota Composition in Inflammatory Bowel Disease Patients: Characterization in Different Phenotypes and Correlation With Clinical Activity and Disease Course.

Catalan-Serra I, Thorsvik S, Beisvag V, Bruland T, Underhill D, Sandvik A Inflamm Bowel Dis. 2023; 30(7):1164-1177.

PMID: 38103028 PMC: 11219482. DOI: 10.1093/ibd/izad289.

Efficacy and safety of mycophenolate mofetil in the treatment of moderate to severe Graves' orbitopathy: a meta-analysis.

Feng W, Hu Y, Zhang C, Shi H, Zhang P, Yang Y Bioengineered. 2022; 13(6):14719-14729.

PMID: 35959915 PMC: 9377259. DOI: 10.1080/21655979.2022.2101191.

ACG Clinical Guideline: Management of Crohn's Disease in Adults.

Lichtenstein G, Loftus E, Isaacs K, Regueiro M, Gerson L, Sands B Am J Gastroenterol. 2018; 113(4):481-517.

PMID: 29610508 DOI: 10.1038/ajg.2018.27.

Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis.

Wheat C, Ko C, Clark-Snustad K, Grembowski D, Thornton T, Devine B BMC Gastroenterol. 2017; 17(1):52.

PMID: 28407755 PMC: 5391579. DOI: 10.1186/s12876-017-0602-0.

References

ODonoghue D, Dawson A, Powell-Tuck J, Bown R, Lennard-Jones J . Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet. 1978; 2(8097):955-7. DOI: 10.1016/s0140-6736(78)92524-2. View

Targan S, Hanauer S, van Deventer S, Mayer L, Present D, Braakman T . A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337(15):1029-35. DOI: 10.1056/NEJM199710093371502. View

Present D, Korelitz B, Wisch N, Glass J, Sachar D, Pasternack B . Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980; 302(18):981-7. DOI: 10.1056/NEJM198005013021801. View

Rhodes J, Bainton D, Beck P, Campbell H . Controlled trial of azathioprine in Crohn's disease. Lancet. 1971; 2(7737):1273-6. DOI: 10.1016/s0140-6736(71)90598-8. View

EPINETTE W, Parker C, Jones E, Greist M . Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol. 1987; 17(6):962-71. DOI: 10.1016/s0190-9622(87)70285-0. View

Present D, Meltzer S, Krumholz M, Wolke A, Korelitz B . 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989; 111(8):641-9. DOI: 10.7326/0003-4819-111-8-641. View

GOLDBLUM R . Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol. 1993; 11 Suppl 8:S117-9. View

Ewe K, Press A, Singe C, Stufler M, Ueberschaer B, Hommel G . Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology. 1993; 105(2):367-72. DOI: 10.1016/0016-5085(93)90709-l. View

Allison A, Eugui E . Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev. 1993; 136:5-28. DOI: 10.1111/j.1600-065x.1993.tb00652.x. View

10.

Sachar D . Budesonide for inflammatory bowel disease. Is it a magic bullet?. N Engl J Med. 1994; 331(13):873-4. DOI: 10.1056/NEJM199409293311311. View

11.

Feagan B, Rochon J, Fedorak R, Irvine E, Wild G, Sutherland L . Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med. 1995; 332(5):292-7. DOI: 10.1056/NEJM199502023320503. View

12.

Pearson D, May G, Fick G, Sutherland L . Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995; 123(2):132-42. DOI: 10.7326/0003-4819-123-2-199507150-00009. View

13.

Breese E, MacDonald T . TNF alpha secreting cells in normal and diseased human intestine. Adv Exp Med Biol. 1995; 371B:821-4. View

14.

Bouhnik Y, Lemann M, Mary J, Scemama G, Tai R, Matuchansky C . Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996; 347(8996):215-9. DOI: 10.1016/s0140-6736(96)90402-x. View

15.

Hanauer S . Inflammatory bowel disease. N Engl J Med. 1996; 334(13):841-8. DOI: 10.1056/NEJM199603283341307. View

16.

Allison A, Eugui E . Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant. 1996; 10(1 Pt 2):77-84. View

17.

Fuss I, Neurath M, Boirivant M, Klein J, de La Motte C, Strong S . Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996; 157(3):1261-70. View

18.

Lipsky J . Mycophenolate mofetil. Lancet. 1996; 348(9038):1357-9. DOI: 10.1016/S0140-6736(96)10310-X. View

19.

Farthing M, Newcombe R . Reporting of clinical trials in Gut: the CONSORT statement. Consolidated Standards of Reporting Trials. Gut. 1997; 40(5):563-4. PMC: 1027152. DOI: 10.1136/gut.40.5.563. View

20.

van Deventer S, Elson C, Fedorak R . Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology. 1997; 113(2):383-9. DOI: 10.1053/gast.1997.v113.pm9247454. View